96 related articles for article (PubMed ID: 12351610)
21. [Nasal septum perforation and bevacizumab].
Bengrine-Lefevre L; Afchain P; Chibaudel B; Gervais H; Tournigand C; De Gramont A; Louvet C
Rev Med Interne; 2011 Apr; 32(4):e43-5. PubMed ID: 21470582
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
Andre F; Campone M; O'Regan R; Manlius C; Massacesi C; Sahmoud T; Mukhopadhyay P; Soria JC; Naughton M; Hurvitz SA
J Clin Oncol; 2010 Dec; 28(34):5110-5. PubMed ID: 20975068
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
Leyland-Jones B; Gelmon K; Ayoub JP; Arnold A; Verma S; Dias R; Ghahramani P
J Clin Oncol; 2003 Nov; 21(21):3965-71. PubMed ID: 14507946
[TBL] [Abstract][Full Text] [Related]
24. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
Gianni L
Breast Cancer Res Treat; 2009 Oct; 117(3):599-601. PubMed ID: 19387827
[No Abstract] [Full Text] [Related]
25. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
Sikov WM; Dizon DS; Strenger R; Legare RD; Theall KP; Graves TA; Gass JS; Kennedy TA; Fenton MA
J Clin Oncol; 2009 Oct; 27(28):4693-700. PubMed ID: 19720916
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Dawood S; Gonzalez-Angulo AM; Peintinger F; Broglio K; Symmans WF; Kau SW; Islam R; Hortobagyi GN; Buzdar AU
Cancer; 2007 Sep; 110(6):1195-200. PubMed ID: 17647266
[TBL] [Abstract][Full Text] [Related]
27. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar AU; Ibrahim NK; Francis D; Booser DJ; Thomas ES; Theriault RL; Pusztai L; Green MC; Arun BK; Giordano SH; Cristofanilli M; Frye DK; Smith TL; Hunt KK; Singletary SE; Sahin AA; Ewer MS; Buchholz TA; Berry D; Hortobagyi GN
J Clin Oncol; 2005 Jun; 23(16):3676-85. PubMed ID: 15738535
[TBL] [Abstract][Full Text] [Related]
28. Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer.
Tham YL; Verani MS; Chang J
Breast Cancer Res Treat; 2002 Jul; 74(2):131-4. PubMed ID: 12186373
[TBL] [Abstract][Full Text] [Related]
29. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer.
Christodoulou C; Klouvas G; Pateli A; Mellou S; Sgouros J; Skarlos DV
Anticancer Res; 2003; 23(1B):737-44. PubMed ID: 12680177
[TBL] [Abstract][Full Text] [Related]
30. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer.
Abusief ME; Missmer SA; Ginsburg ES; Weeks JC; Partridge AH
Cancer; 2010 Feb; 116(4):791-8. PubMed ID: 20052714
[TBL] [Abstract][Full Text] [Related]
31. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.
Traina TA; Norton L; Drucker K; Singh B
Oncologist; 2006; 11(10):1070-1. PubMed ID: 17110625
[No Abstract] [Full Text] [Related]
32. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study.
Wadhwa D; Fallah-Rad N; Grenier D; Krahn M; Fang T; Ahmadie R; Walker JR; Lister D; Arora RC; Barac I; Morris A; Jassal DS
Breast Cancer Res Treat; 2009 Sep; 117(2):357-64. PubMed ID: 19082707
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
Fornier M; Esteva FJ; Seidman AD
Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab/docetaxel-induced nail dystrophy.
Alexandrescu DT; Vaillant J; Wiernik PH
Int J Dermatol; 2006 Nov; 45(11):1334-6. PubMed ID: 17076719
[No Abstract] [Full Text] [Related]
35. [Examination of therapy using trastuzumab in patients with metastatic breast carcinoma].
Nohara T; Iwamoto M; Kobayashi T; Lee SW; Sumiyoshi K; Tanigawa N
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1651-4. PubMed ID: 14619486
[TBL] [Abstract][Full Text] [Related]
36. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Farhat MH; El-Saghir NS; Shamseddine AI
Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
[TBL] [Abstract][Full Text] [Related]
37. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
38. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
[TBL] [Abstract][Full Text] [Related]
39. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
40. [Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].
Mychaluk J; Piprot C; Sevestre H; Merviel P; Gondry J; Fauvet R
Presse Med; 2009 Sep; 38(9):1370-4. PubMed ID: 19349140
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
